08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

NeoGenomics sales and marketing update

NeoGenomics launched new tests to detect mutations in the Bruton’s tyrosine kinase (BtK) and phospholipase C gamma 2 (phosphatidylinositol-specific; PLCG2) genes for predicting acquired resistance to BtK inhibitors and a lymphoma profiling test...
07:00 , Aug 28, 2014 |  BC Innovations  |  Cover Story

Overcoming ibrutinib resistance

Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical...
07:00 , Jul 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Bruton's tyrosine kinase (BTK); phospholipase Cg2 (phosphatidylinositol-specific) (PLCG2) Studies in human samples identified...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis...